These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27143168)

  • 21. Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells.
    Accardo A; Mansi R; Salzano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Ziaco B; Tesauro D; Aloj L; De Rosa G; Morelli G
    J Drug Target; 2013 Apr; 21(3):240-249. PubMed ID: 23167653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.
    Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM
    Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
    Sella A; Sella T; Peer A; Berger R; Frank SJ; Gez E; Sharide D; Hayat H; Hanovich E; Kovel S; Rosenbaum E; Neiman V; Keizman D
    Clin Genitourin Cancer; 2014 Dec; 12(6):428-32. PubMed ID: 25066221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of α-conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to α7 nAChR-overexpressing breast cancer.
    Mei D; Lin Z; Fu J; He B; Gao W; Ma L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Lu W; Zhou D; Zhang Q
    Biomaterials; 2015 Feb; 42():52-65. PubMed ID: 25542793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A facile and universal method to achieve liposomal remote loading of non-ionizable drugs with outstanding safety profiles and therapeutic effect.
    Zhou S; Li J; Yu J; Yang L; Kuang X; Wang Z; Wang Y; Liu H; Lin G; He Z; Liu D; Wang Y
    Acta Pharm Sin B; 2021 Jan; 11(1):258-270. PubMed ID: 33532191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro.
    Han X; Liu J; Liu M; Xie C; Zhan C; Gu B; Liu Y; Feng L; Lu W
    Int J Pharm; 2009 May; 372(1-2):125-31. PubMed ID: 19166923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.
    Rogers BE; Manna DD; Safavy A
    Cancer Biother Radiopharm; 2004 Feb; 19(1):25-34. PubMed ID: 15068608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model.
    Ananias HJ; Yu Z; Dierckx RA; van der Wiele C; Helfrich W; Wang F; Yan Y; Chen X; de Jong IJ; Elsinga PH
    Mol Pharm; 2011 Aug; 8(4):1165-73. PubMed ID: 21699202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment.
    Cohen L; Assaraf YG; Livney YD
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes.
    Eryilmaz IE; Egeli U; Cecener G
    Cancer Biol Ther; 2024 Dec; 25(1):2329368. PubMed ID: 38485703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-EGFR immunoliposomes for cabazitaxel delivery: From formulation development to in vivo evaluation in prostate cancer xenograft model.
    Carolina Cruz de Sousa A; da Silva Santos E; da Silva Moreira T; Gabriela Araújo Mendes M; Rodrigues Arruda B; de Jesus Guimarães C; de Brito Vieira Neto J; Santiago de Oliveira Y; Pedro Ayala A; Rodrigues da Costa MD; Lima Sampaio T; Paula Negreiros Nunes Alves A; Pessoa C; Petrilli R; Eloy JO
    Int J Pharm; 2024 Jul; 661():124439. PubMed ID: 38972520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
    Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
    Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody.
    Liu D; Liu F; Liu Z; Wang L; Zhang N
    Mol Pharm; 2011 Dec; 8(6):2291-301. PubMed ID: 21923159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
    Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effect of folate-targeted and PEGylated phytosomes loaded with a mitomycin C-soybean phosphatidyhlcholine complex.
    Li Y; Wu H; Jia M; Cui F; Lin J; Yang X; Wang Y; Dai L; Hou Z
    Mol Pharm; 2014 Sep; 11(9):3017-26. PubMed ID: 25054963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds.
    Devalapally H; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ; Silchenko S
    Drug Deliv; 2015; 22(4):467-74. PubMed ID: 24344786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic Acid-Conjugated Nanoparticles for the Targeted Delivery of Cabazitaxel to CD44-Overexpressing Glioblastoma Cells.
    Chen C; Fan R; Wang Y; Wang L; Huang C; Zhou L; Xu J; Chen H; Guo G
    J Biomed Nanotechnol; 2021 Apr; 17(4):595-605. PubMed ID: 35057886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.